Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis

Previous studies indicate that prostate cancer antigen 3 (PCA3) is highly expressed in prostatic tumors. However, its clinical value has not been characterized. The aim of this study was to investigate the clinical value of the urine PCA3 test in the diagnosis of prostate cancer by pooling the publi...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Scientific reports Ročník 6; číslo 1; s. 25776
Hlavní autoři: Cui, Yong, Cao, Wenzhou, Li, Quan, Shen, Hua, Liu, Chao, Deng, Junpeng, Xu, Jiangfeng, Shao, Qiang
Médium: Journal Article
Jazyk:angličtina
Vydáno: London Nature Publishing Group UK 10.05.2016
Nature Publishing Group
Témata:
38
38/77
631/61/54
639/301/1019
Antigens
Antigens, Neoplasm - metabolism
Antigens, Neoplasm - urine
Clinical trials
Humanities and Social Sciences
Humans
Male
Meta-analysis
multidisciplinary
Odds Ratio
Prostate cancer
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - metabolism
Prostatic Neoplasms - urine
ROC Curve
Science
Science (multidisciplinary)
Sensitivity and Specificity
Tumors
Urine
ISSN:2045-2322, 2045-2322
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Previous studies indicate that prostate cancer antigen 3 (PCA3) is highly expressed in prostatic tumors. However, its clinical value has not been characterized. The aim of this study was to investigate the clinical value of the urine PCA3 test in the diagnosis of prostate cancer by pooling the published data. Clinical trials utilizing the urine PCA3 test for diagnosing prostate cancer were retrieved from PubMed and Embase. A total of 46 clinical trials including 12,295 subjects were included in this meta-analysis. The pooled sensitivity, specificity, positive likelihood ratio (+LR), negative likelihood ratio (−LR), diagnostic odds ratio (DOR) and area under the curve (AUC) were 0.65 (95% confidence interval [CI]: 0.63–0.66), 0.73 (95% CI: 0.72–0.74), 2.23 (95% CI: 1.91–2.62), 0.48 (95% CI: 0.44–0.52), 5.31 (95% CI: 4.19–6.73) and 0.75 (95% CI: 0.74–0.77), respectively. In conclusion, the urine PCA3 test has acceptable sensitivity and specificity for the diagnosis of prostate cancer and can be used as a non-invasive method for that purpose.
AbstractList Previous studies indicate that prostate cancer antigen 3 (PCA3) is highly expressed in prostatic tumors. However, its clinical value has not been characterized. The aim of this study was to investigate the clinical value of the urine PCA3 test in the diagnosis of prostate cancer by pooling the published data. Clinical trials utilizing the urine PCA3 test for diagnosing prostate cancer were retrieved from PubMed and Embase. A total of 46 clinical trials including 12,295 subjects were included in this meta-analysis. The pooled sensitivity, specificity, positive likelihood ratio (+LR), negative likelihood ratio (-LR), diagnostic odds ratio (DOR) and area under the curve (AUC) were 0.65 (95% confidence interval [CI]: 0.63-0.66), 0.73 (95% CI: 0.72-0.74), 2.23 (95% CI: 1.91-2.62), 0.48 (95% CI: 0.44-0.52), 5.31 (95% CI: 4.19-6.73) and 0.75 (95% CI: 0.74-0.77), respectively. In conclusion, the urine PCA3 test has acceptable sensitivity and specificity for the diagnosis of prostate cancer and can be used as a non-invasive method for that purpose.
Previous studies indicate that prostate cancer antigen 3 (PCA3) is highly expressed in prostatic tumors. However, its clinical value has not been characterized. The aim of this study was to investigate the clinical value of the urine PCA3 test in the diagnosis of prostate cancer by pooling the published data. Clinical trials utilizing the urine PCA3 test for diagnosing prostate cancer were retrieved from PubMed and Embase. A total of 46 clinical trials including 12,295 subjects were included in this meta-analysis. The pooled sensitivity, specificity, positive likelihood ratio (+LR), negative likelihood ratio (−LR), diagnostic odds ratio (DOR) and area under the curve (AUC) were 0.65 (95% confidence interval [CI]: 0.63–0.66), 0.73 (95% CI: 0.72–0.74), 2.23 (95% CI: 1.91–2.62), 0.48 (95% CI: 0.44–0.52), 5.31 (95% CI: 4.19–6.73) and 0.75 (95% CI: 0.74–0.77), respectively. In conclusion, the urine PCA3 test has acceptable sensitivity and specificity for the diagnosis of prostate cancer and can be used as a non-invasive method for that purpose.
ArticleNumber 25776
Author Shen, Hua
Liu, Chao
Li, Quan
Deng, Junpeng
Cui, Yong
Cao, Wenzhou
Xu, Jiangfeng
Shao, Qiang
Author_xml – sequence: 1
  givenname: Yong
  surname: Cui
  fullname: Cui, Yong
  organization: Department of Urology, Suzhou Municipal Hospital, Nanjing Medical University Affiliated Suzhou Hospital
– sequence: 2
  givenname: Wenzhou
  surname: Cao
  fullname: Cao, Wenzhou
  organization: Department of Urology, Suzhou Municipal Hospital, Nanjing Medical University Affiliated Suzhou Hospital
– sequence: 3
  givenname: Quan
  surname: Li
  fullname: Li, Quan
  organization: Department of Urology, Suzhou Municipal Hospital, Nanjing Medical University Affiliated Suzhou Hospital
– sequence: 4
  givenname: Hua
  surname: Shen
  fullname: Shen, Hua
  organization: Department of Urology, Suzhou Municipal Hospital, Nanjing Medical University Affiliated Suzhou Hospital
– sequence: 5
  givenname: Chao
  surname: Liu
  fullname: Liu, Chao
  organization: Department of Urology, Suzhou Municipal Hospital, Nanjing Medical University Affiliated Suzhou Hospital
– sequence: 6
  givenname: Junpeng
  surname: Deng
  fullname: Deng, Junpeng
  organization: Department of Urology, Suzhou Municipal Hospital, Nanjing Medical University Affiliated Suzhou Hospital
– sequence: 7
  givenname: Jiangfeng
  surname: Xu
  fullname: Xu, Jiangfeng
  organization: Center for Cancer Genomics, Wake Forest University School of Medicine
– sequence: 8
  givenname: Qiang
  surname: Shao
  fullname: Shao, Qiang
  email: sq7166822@163.com
  organization: Department of Urology, Suzhou Municipal Hospital, Nanjing Medical University Affiliated Suzhou Hospital
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27161545$$D View this record in MEDLINE/PubMed
BookMark eNptkVFvFCEUhYmpsbX2wT9gSHyxJtMCMwxMH0yaptYmTXzRZ8Iwl5VmBlZg1uy_l3XrZrvKC9zc756cy3mNjnzwgNBbSi4oqeVlirBkXIj2BTphpOEVqxk72nsfo7OUHkk5nHUN7V6hYyZoS3nDT9B4u9LjrLMLHgeLlzGkrDNgo72BiLXPbgEe19iGiAfIYLLzi0PuCmuc1inDVJQMjrBy8KsMD3iCrCvt9bhOLr1BL60eE5w93afo--fbbzdfqoevd_c31w-V4aTJ1SAkSGY6wWXf99z0HWVWsJoQa4UdGi4GKI1a9sbSXoraNJwLowdpLLBSn6JPW93l3E8wGPA56lEto5t0XKugnXre8e6HWoSVamRLu3Yj8OFJIIafM6SsJpcMjKP2EOakqJCSMdk1pKDvD9DHMMeycKFkJ9tW8m5Dvdt3tLPyN4gCnG8BU362RGp3CCVqk7Pa5VzYywPWuPwnwrKMG_878XE7kYqqX0DcM_kP_BsMyrtw
CitedBy_id crossref_primary_10_1515_cclm_2019_0693
crossref_primary_10_1080_14737159_2023_2277366
crossref_primary_10_1038_s41698_022_00283_7
crossref_primary_10_2217_epi_2023_0349
crossref_primary_10_17650_1726_9776_2024_20_1_36_43
crossref_primary_10_1016_j_semcancer_2018_01_012
crossref_primary_10_3390_cancers16020316
crossref_primary_10_3390_cancers12092718
crossref_primary_10_1017_S1460396920001168
crossref_primary_10_1002_ijc_33045
crossref_primary_10_3390_diagnostics8030060
crossref_primary_10_1186_s13148_019_0779_x
crossref_primary_10_1111_iju_13734
crossref_primary_10_3390_cancers16091757
crossref_primary_10_1111_iju_14464
crossref_primary_10_2147_RRU_S262310
crossref_primary_10_1158_1541_7786_MCR_16_0331
crossref_primary_10_3390_cancers13143570
crossref_primary_10_1155_2020_3964615
crossref_primary_10_1007_s11255_017_1536_8
crossref_primary_10_3390_cancers13174251
crossref_primary_10_3390_cancers15133433
crossref_primary_10_3390_cancers13215544
crossref_primary_10_1002_uro2_32
crossref_primary_10_3892_ol_2017_5911
crossref_primary_10_1080_00325481_2020_1822067
crossref_primary_10_3390_ijms21041184
crossref_primary_10_1016_j_tranon_2018_02_019
crossref_primary_10_1038_s41598_020_75526_3
crossref_primary_10_2174_0929867325666180914115416
crossref_primary_10_3389_fmed_2022_736110
crossref_primary_10_3389_fphar_2023_1237723
crossref_primary_10_3390_proteomes13040047
crossref_primary_10_1186_s12935_022_02653_4
crossref_primary_10_1038_s41598_022_08102_6
crossref_primary_10_1016_j_semcancer_2018_02_002
crossref_primary_10_1038_s41598_024_55083_9
crossref_primary_10_1007_s00345_019_02719_5
crossref_primary_10_1016_j_urolonc_2020_02_018
crossref_primary_10_4103_aja202411
crossref_primary_10_5858_arpa_2017_0185_OA
crossref_primary_10_1016_j_clgc_2020_03_005
crossref_primary_10_3892_ijo_2017_3925
crossref_primary_10_1186_s12967_022_03860_3
crossref_primary_10_1007_s11517_025_03365_3
crossref_primary_10_3390_medicines6030082
crossref_primary_10_3390_cancers12082017
crossref_primary_10_3390_biomedicines11010205
crossref_primary_10_1007_s12094_024_03508_2
crossref_primary_10_1186_s12885_017_3301_x
crossref_primary_10_3390_diagnostics11020345
crossref_primary_10_1097_MOU_0000000000001188
crossref_primary_10_1002_cac2_12254
crossref_primary_10_1039_C8RA08083F
crossref_primary_10_1007_s00345_021_03714_5
crossref_primary_10_1186_s13046_024_03065_0
crossref_primary_10_2217_fon_2016_0178
crossref_primary_10_3390_ijms24032185
crossref_primary_10_3389_fonc_2024_1474891
crossref_primary_10_3390_diagnostics13213350
Cites_doi 10.1007/s00345-010-0580-0
10.1002/pros.22538
10.1186/1471-2288-3-25
10.1016/j.juro.2011.01.075
10.1016/j.eururo.2012.07.030
10.1373/clinchem.2012.195560
10.4081/aiua.2014.4.306
10.1002/cncr.24447
10.1111/j.1464-410X.2011.10202.x
10.1186/1471-2407-12-507
10.1089/end.2010.0196
10.1371/journal.pone.0004995
10.1016/j.eururo.2008.06.071
10.1016/j.juro.2009.07.093
10.3109/00365599.2010.521187
10.1016/j.acuro.2011.04.001
10.1159/000314078
10.1038/srep05012
10.1074/jbc.M202414200
10.1158/0008-5472.CAN-07-3224
10.1002/pros.20564
10.1371/journal.pone.0067687
10.1016/j.urology.2006.12.014
10.1016/j.juro.2013.02.3184
10.1590/S1677-55382012000400008
10.1016/j.eururo.2010.06.038
10.6004/jnccn.2010.0010
10.1016/j.juro.2014.01.030
10.1016/j.urology.2008.08.459
10.1016/j.juro.2012.07.023
10.1016/j.eururo.2004.06.004
10.1111/j.1464-410X.2012.11683.x
10.1016/j.canlet.2011.09.035
10.1111/j.1442-2042.2010.02711.x
10.1016/j.juro.2009.01.110
10.1016/j.juro.2007.11.038
10.1111/j.1464-410X.2012.11146.x
10.1038/pcan.2011.52
10.1373/clinchem.2005.063289
10.1016/S0302-2838(03)00201-X
10.1002/pros.21286
10.1002/pros.21211
10.1016/j.yexmp.2010.10.009
10.1016/S0090-4295(03)00759-3
10.1016/j.urology.2004.03.052
10.3322/caac.21208
10.1016/j.juro.2010.06.098
10.1016/j.eururo.2010.09.036
10.1016/j.juro.2013.12.005
10.1158/1078-0432.CCR-06-2679
10.1136/bmj.b2700
10.1016/j.eururo.2010.06.039
10.1016/j.eururo.2010.10.039
10.1002/pros.22561
10.1080/13547500902807306
10.1002/pros.21040
ContentType Journal Article
Copyright The Author(s) 2016
Copyright Nature Publishing Group May 2016
Copyright © 2016, Macmillan Publishers Limited 2016 Macmillan Publishers Limited
Copyright_xml – notice: The Author(s) 2016
– notice: Copyright Nature Publishing Group May 2016
– notice: Copyright © 2016, Macmillan Publishers Limited 2016 Macmillan Publishers Limited
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88A
88E
88I
8FE
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M2P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOI 10.1038/srep25776
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
PML(ProQuest Medical Library)
Science Database (ProQuest)
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database
MEDLINE - Academic
MEDLINE
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: PIMPY
  name: ProQuest Publicly Available Content
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2045-2322
EndPage 25776
ExternalDocumentID PMC4861967
27161545
10_1038_srep25776
Genre Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Journal Article
GroupedDBID 0R~
3V.
4.4
53G
5VS
7X7
88A
88E
88I
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AAKDD
ABDBF
ABUWG
ACGFS
ACSMW
ACUHS
ADBBV
ADRAZ
AENEX
AEUYN
AFKRA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
DWQXO
EBD
EBLON
EBS
EJD
ESX
FYUFA
GNUQQ
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
KQ8
LK8
M0L
M1P
M2P
M48
M7P
M~E
NAO
OK1
PIMPY
PQQKQ
PROAC
PSQYO
RNT
RNTTT
RPM
SNYQT
UKHRP
AASML
AAYXX
AFFHD
AFPKN
CITATION
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
CGR
CUY
CVF
ECM
EIF
NPM
7XB
8FK
K9.
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c504t-d78e82c9758bbb5cb912f72300ff7fd457debbb38bcf1b873c4557cad8cfe2873
IEDL.DBID M2P
ISICitedReferencesCount 77
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000375535000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2045-2322
IngestDate Tue Nov 04 01:37:53 EST 2025
Fri Sep 05 08:01:15 EDT 2025
Tue Oct 07 07:26:50 EDT 2025
Mon Jul 21 06:07:42 EDT 2025
Tue Nov 18 22:35:14 EST 2025
Sat Nov 29 01:49:20 EST 2025
Fri Feb 21 02:39:26 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c504t-d78e82c9758bbb5cb912f72300ff7fd457debbb38bcf1b873c4557cad8cfe2873
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Feature-2
content type line 23
ObjectType-Review-1
ObjectType-Article-3
ObjectType-Undefined-4
These authors contributed equally to this work.
OpenAccessLink https://www.proquest.com/docview/1898668590?pq-origsite=%requestingapplication%
PMID 27161545
PQID 1898668590
PQPubID 2041939
PageCount 1
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_4861967
proquest_miscellaneous_1788228940
proquest_journals_1898668590
pubmed_primary_27161545
crossref_primary_10_1038_srep25776
crossref_citationtrail_10_1038_srep25776
springer_journals_10_1038_srep25776
PublicationCentury 2000
PublicationDate 2016-05-10
PublicationDateYYYYMMDD 2016-05-10
PublicationDate_xml – month: 05
  year: 2016
  text: 2016-05-10
  day: 10
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Scientific reports
PublicationTitleAbbrev Sci Rep
PublicationTitleAlternate Sci Rep
PublicationYear 2016
Publisher Nature Publishing Group UK
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
References Ouyang (CR16) 2009; 181
Mearini (CR19) 2009; 14
Crawford (CR37) 2012; 188
Scattoni (CR48) 2013; 190
Herness, Naz (CR60) 2003; 63
Korkmaz (CR62) 2002; 277
Ferreira (CR59) 2012; 12
Mohler (CR54) 2010; 8
Shen (CR27) 2011; 90
Perdona (CR33) 2011; 59
Perdona (CR46) 2013; 73
Marks (CR12) 2007; 69
Rigau (CR26) 2010; 70
Porpiglia (CR50) 2014; 192
Groskopf (CR9) 2006; 52
van Gils (CR11) 2007; 67
Wang, Chinnaiyan, Dunn, Wojno, Wei (CR18) 2009; 115
Ferro (CR42) 2013; 8
Luo (CR61) 2002; 62
Liberati (CR4) 2009; 339
van Gils (CR10) 2007; 13
Pepe, Fraggetta, Galia, Skonieczny, Aragona (CR39) 2012; 38
Heidenreich (CR53) 2011; 59
Siegel, Ma, Zou, Jemal (CR2) 2014; 64
Ochiai (CR44) 2013; 111
Aubin (CR21) 2010; 184
Hessels (CR6) 2003; 44
Fradet (CR7) 2004; 64
Haese (CR14) 2008; 54
Shappell (CR17) 2009; 73
Goode, Marshall, Duff, Chevli, Chevli (CR43) 2013; 73
Shao (CR1) 2012; 315
Roobol (CR25) 2010; 58
Cao (CR31) 2011; 71
Greene (CR55) 2009; 182
Rubio-Briones (CR29) 2011; 35
Stephan (CR45) 2013; 59
Salagierski, Mulders, Schalken (CR47) 2013; 33
Clarke (CR58) 2009; 4
Barbera, Pepe, Paola, Aragona (CR35) 2012; 84
CR57
Schilling (CR28) 2010; 85
de la Taille (CR34) 2011; 185
Wu, Reese, Cooperberg, Sadetsky, Shinohara (CR41) 2012; 15
Nyberg (CR24) 2010; 44
Whiting, Rutjes, Reitsma, Bossuyt, Kleijnen (CR5) 2003; 3
Morote (CR23) 2010; 28
Pepe, Aragona (CR38) 2011; 31
Deras (CR13) 2008; 179
Sciarra (CR40) 2012; 110
Schalken, Hessels, Verhaegh (CR56) 2003; 62
Adam (CR30) 2011; 108
Henderson (CR20) 2010; 24
Bussemakers (CR3) 1999; 59
Wang (CR63) 2014; 4
Tinzl, Marberger, Horvath (CR8) 2004; 46
Albino (CR51) 2014; 86
Ochiai (CR32) 2011; 18
Laxman (CR15) 2008; 68
Auprich (CR22) 2010; 58
Ng (CR36) 2012; 18
Chevli (CR49) 2014; 191
Hansen (CR52) 2013; 63
JL Mohler (BFsrep25776_CR54) 2010; 8
A Heidenreich (BFsrep25776_CR53) 2011; 59
A Liberati (BFsrep25776_CR4) 2009; 339
CF Ng (BFsrep25776_CR36) 2012; 18
B Laxman (BFsrep25776_CR15) 2008; 68
S Perdona (BFsrep25776_CR33) 2011; 59
M Ferro (BFsrep25776_CR42) 2013; 8
MJ Roobol (BFsrep25776_CR25) 2010; 58
A de la Taille (BFsrep25776_CR34) 2011; 185
M Nyberg (BFsrep25776_CR24) 2010; 44
R Siegel (BFsrep25776_CR2) 2014; 64
DL Cao (BFsrep25776_CR31) 2011; 71
ED Crawford (BFsrep25776_CR37) 2012; 188
Y Fradet (BFsrep25776_CR7) 2004; 64
M Shen (BFsrep25776_CR27) 2011; 90
P Whiting (BFsrep25776_CR5) 2003; 3
JA Schalken (BFsrep25776_CR56) 2003; 62
RR Goode (BFsrep25776_CR43) 2013; 73
J Hansen (BFsrep25776_CR52) 2013; 63
J Morote (BFsrep25776_CR23) 2010; 28
D Schilling (BFsrep25776_CR28) 2010; 85
P Pepe (BFsrep25776_CR38) 2011; 31
M Auprich (BFsrep25776_CR22) 2010; 58
A Adam (BFsrep25776_CR30) 2011; 108
G Albino (BFsrep25776_CR51) 2014; 86
MJ Bussemakers (BFsrep25776_CR3) 1999; 59
J Henderson (BFsrep25776_CR20) 2010; 24
LB Ferreira (BFsrep25776_CR59) 2012; 12
M Tinzl (BFsrep25776_CR8) 2004; 46
S Perdona (BFsrep25776_CR46) 2013; 73
E Mearini (BFsrep25776_CR19) 2009; 14
A Haese (BFsrep25776_CR14) 2008; 54
J Luo (BFsrep25776_CR61) 2002; 62
F Porpiglia (BFsrep25776_CR50) 2014; 192
KS Korkmaz (BFsrep25776_CR62) 2002; 277
J Rubio-Briones (BFsrep25776_CR29) 2011; 35
R Wang (BFsrep25776_CR18) 2009; 115
AK Wu (BFsrep25776_CR41) 2012; 15
M Barbera (BFsrep25776_CR35) 2012; 84
KL Greene (BFsrep25776_CR55) 2009; 182
RA Clarke (BFsrep25776_CR58) 2009; 4
V Scattoni (BFsrep25776_CR48) 2013; 190
MP van Gils (BFsrep25776_CR11) 2007; 67
MP van Gils (BFsrep25776_CR10) 2007; 13
B Ouyang (BFsrep25776_CR16) 2009; 181
C Stephan (BFsrep25776_CR45) 2013; 59
A Sciarra (BFsrep25776_CR40) 2012; 110
A Ochiai (BFsrep25776_CR44) 2013; 111
EA Herness (BFsrep25776_CR60) 2003; 63
Q Shao (BFsrep25776_CR1) 2012; 315
M Rigau (BFsrep25776_CR26) 2010; 70
LS Marks (BFsrep25776_CR12) 2007; 69
KK Chevli (BFsrep25776_CR49) 2014; 191
IL Deras (BFsrep25776_CR13) 2008; 179
A Ochiai (BFsrep25776_CR32) 2011; 18
J Groskopf (BFsrep25776_CR9) 2006; 52
D Hessels (BFsrep25776_CR6) 2003; 44
BFsrep25776_CR57
M Salagierski (BFsrep25776_CR47) 2013; 33
W Wang (BFsrep25776_CR63) 2014; 4
SB Shappell (BFsrep25776_CR17) 2009; 73
SM Aubin (BFsrep25776_CR21) 2010; 184
P Pepe (BFsrep25776_CR39) 2012; 38
References_xml – volume: 28
  start-page: 677
  year: 2010
  end-page: 680
  ident: CR23
  article-title: Behavior of the PCA3 gene in the urine of men with high grade prostatic intraepithelial neoplasia
  publication-title: World J Urol
  doi: 10.1007/s00345-010-0580-0
– volume: 73
  start-page: 48
  year: 2013
  end-page: 53
  ident: CR43
  article-title: Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients
  publication-title: Prostate
  doi: 10.1002/pros.22538
– volume: 3
  start-page: 25
  year: 2003
  ident: CR5
  article-title: The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews
  publication-title: BMC Med Res Methodol
  doi: 10.1186/1471-2288-3-25
– volume: 185
  start-page: 2119
  year: 2011
  end-page: 2125
  ident: CR34
  article-title: Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions
  publication-title: J Urol
  doi: 10.1016/j.juro.2011.01.075
– volume: 63
  start-page: 201
  year: 2013
  end-page: 209
  ident: CR52
  article-title: Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2012.07.030
– volume: 59
  start-page: 280
  year: 2013
  end-page: 288
  ident: CR45
  article-title: Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer
  publication-title: Clin Chem
  doi: 10.1373/clinchem.2012.195560
– volume: 86
  start-page: 306
  year: 2014
  end-page: 310
  ident: CR51
  article-title: Evaluation of the diagnostic and predictive power of PCA3 in the prostate cancer. A different best cut-off in each different scenario. Preliminary results
  publication-title: Arch Ital Urol Androl
  doi: 10.4081/aiua.2014.4.306
– volume: 84
  start-page: 227
  year: 2012
  end-page: 229
  ident: CR35
  article-title: PCA3 score accuracy in diagnosing prostate cancer at repeat biopsy: our experience in 177 patients
  publication-title: Arch Ital Urol Androl
– volume: 115
  start-page: 3879
  year: 2009
  end-page: 3886
  ident: CR18
  article-title: Rational approach to implementation of prostate cancer antigen 3 into clinical care
  publication-title: Cancer
  doi: 10.1002/cncr.24447
– volume: 108
  start-page: 1728
  year: 2011
  end-page: 1733
  ident: CR30
  article-title: The role of the PCA3 assay in predicting prostate biopsy outcome in a South African setting
  publication-title: BJU Int
  doi: 10.1111/j.1464-410X.2011.10202.x
– volume: 12
  start-page: 507
  year: 2012
  ident: CR59
  article-title: PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling
  publication-title: BMC cancer
  doi: 10.1186/1471-2407-12-507
– volume: 24
  start-page: 1821
  year: 2010
  end-page: 1824
  ident: CR20
  article-title: The role of PCA3 testing in patients with a raised prostate-specific antigen level after Greenlight photoselective vaporization of the prostate
  publication-title: J Endourol
  doi: 10.1089/end.2010.0196
– volume: 4
  start-page: e4995
  year: 2009
  ident: CR58
  article-title: New genomic structure for prostate cancer specific gene PCA3 within BMCC1: implications for prostate cancer detection and progression
  publication-title: PloS one
  doi: 10.1371/journal.pone.0004995
– volume: 54
  start-page: 1081
  year: 2008
  end-page: 1088
  ident: CR14
  article-title: Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2008.06.071
– volume: 182
  start-page: 2232
  year: 2009
  end-page: 2241
  ident: CR55
  article-title: Prostate specific antigen best practice statement: 2009 update
  publication-title: J Urol
  doi: 10.1016/j.juro.2009.07.093
– volume: 44
  start-page: 378
  year: 2010
  end-page: 383
  ident: CR24
  article-title: PCA3 as a diagnostic marker for prostate cancer: a validation study on a Swedish patient population
  publication-title: Scand J Urol Nephrol
  doi: 10.3109/00365599.2010.521187
– volume: 35
  start-page: 589
  year: 2011
  end-page: 596
  ident: CR29
  article-title: [Outcomes of expanded use of PCA3 testing in a Spanish population with clinical suspicion of prostate cancer]
  publication-title: Actas Urol Esp
  doi: 10.1016/j.acuro.2011.04.001
– volume: 85
  start-page: 159
  year: 2010
  end-page: 165
  ident: CR28
  article-title: Interpretation of the prostate cancer gene 3 in reference to the individual clinical background: implications for daily practice
  publication-title: Urol Int
  doi: 10.1159/000314078
– volume: 4
  start-page: 5012
  year: 2014
  ident: CR63
  article-title: Diagnostic ability of %p2PSA and prostate health index for aggressive prostate cancer: a meta-analysis
  publication-title: Sci Rep
  doi: 10.1038/srep05012
– volume: 277
  start-page: 36689
  year: 2002
  end-page: 36696
  ident: CR62
  article-title: Molecular cloning and characterization of STAMP1, a highly prostate-specific six transmembrane protein that is overexpressed in prostate cancer
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M202414200
– volume: 33
  start-page: 553
  year: 2013
  end-page: 557
  ident: CR47
  article-title: Predicting prostate biopsy outcome using a PCA3-based nomogram in a Polish cohort
  publication-title: Anticancer Res
– volume: 68
  start-page: 645
  year: 2008
  end-page: 649
  ident: CR15
  article-title: A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-07-3224
– ident: CR57
– volume: 67
  start-page: 881
  year: 2007
  end-page: 887
  ident: CR11
  article-title: Molecular PCA3 diagnostics on prostatic fluid
  publication-title: Prostate
  doi: 10.1002/pros.20564
– volume: 8
  start-page: e67687
  year: 2013
  ident: CR42
  article-title: Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0067687
– volume: 69
  start-page: 532
  year: 2007
  end-page: 535
  ident: CR12
  article-title: PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy
  publication-title: Urology
  doi: 10.1016/j.urology.2006.12.014
– volume: 31
  start-page: 4445
  year: 2011
  end-page: 4449
  ident: CR38
  article-title: PCA3 score vs PSA free/total accuracy in prostate cancer diagnosis at repeat saturation biopsy
  publication-title: Anticancer Res
– volume: 190
  start-page: 496
  year: 2013
  end-page: 501
  ident: CR48
  article-title: Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy
  publication-title: J Urol
  doi: 10.1016/j.juro.2013.02.3184
– volume: 38
  start-page: 489
  year: 2012
  end-page: 495
  ident: CR39
  article-title: PCA3 score and prostate cancer diagnosis at repeated saturation biopsy. Which cut-off: 20 or 35?
  publication-title: Int Braz J Urol
  doi: 10.1590/S1677-55382012000400008
– volume: 58
  start-page: 727
  year: 2010
  end-page: 732
  ident: CR22
  article-title: External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2010.06.038
– volume: 8
  start-page: 145
  year: 2010
  ident: CR54
  article-title: The 2010 NCCN clinical practice guidelines in oncology on prostate cancer
  publication-title: J Natl Compr Canc Netw
  doi: 10.6004/jnccn.2010.0010
– volume: 192
  start-page: 60
  year: 2014
  end-page: 66
  ident: CR50
  article-title: The roles of multiparametric magnetic resonance imaging, PCA3 and prostate health index-which is the best predictor of prostate cancer after a negative biopsy?
  publication-title: J Urol
  doi: 10.1016/j.juro.2014.01.030
– volume: 73
  start-page: 363
  year: 2009
  end-page: 368
  ident: CR17
  article-title: PCA3 urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting
  publication-title: Urology
  doi: 10.1016/j.urology.2008.08.459
– volume: 188
  start-page: 1726
  year: 2012
  end-page: 1731
  ident: CR37
  article-title: Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases
  publication-title: J Urol
  doi: 10.1016/j.juro.2012.07.023
– volume: 46
  start-page: 182
  year: 2004
  end-page: 186
  ident: CR8
  article-title: & Chypre, C. DD3PCA3 RNA analysis in urine–a new perspective for detecting prostate cancer
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2004.06.004
– volume: 111
  start-page: 928
  year: 2013
  end-page: 933
  ident: CR44
  article-title: Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy
  publication-title: BJU Int
  doi: 10.1111/j.1464-410X.2012.11683.x
– volume: 63
  start-page: 329
  year: 2003
  end-page: 336
  ident: CR60
  article-title: A novel human prostate-specific gene-1 (HPG-1): molecular cloning, sequencing, and its potential involvement in prostate carcinogenesis
  publication-title: Cancer research
– volume: 62
  start-page: 2220
  year: 2002
  end-page: 2226
  ident: CR61
  article-title: Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer
  publication-title: Cancer Res
– volume: 315
  start-page: 170
  year: 2012
  end-page: 177
  ident: CR1
  article-title: Prostate cancer in the senior men from rural areas in east district of China: contemporary management and 5-year outcomes at multi-institutional collaboration
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2011.09.035
– volume: 18
  start-page: 200
  year: 2011
  end-page: 205
  ident: CR32
  article-title: Prostate cancer gene 3 urine assay for prostate cancer in Japanese men undergoing prostate biopsy
  publication-title: Int J Urol
  doi: 10.1111/j.1442-2042.2010.02711.x
– volume: 181
  start-page: 2508
  year: 2009
  end-page: 2513
  ident: CR16
  article-title: A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer
  publication-title: J Urol
  doi: 10.1016/j.juro.2009.01.110
– volume: 179
  start-page: 1587
  year: 2008
  end-page: 1592
  ident: CR13
  article-title: PCA3: a molecular urine assay for predicting prostate biopsy outcome
  publication-title: J Urol
  doi: 10.1016/j.juro.2007.11.038
– volume: 110
  start-page: 1661
  year: 2012
  end-page: 1665
  ident: CR40
  article-title: Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy
  publication-title: BJU Int
  doi: 10.1111/j.1464-410X.2012.11146.x
– volume: 15
  start-page: 100
  year: 2012
  end-page: 105
  ident: CR41
  article-title: Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer
  publication-title: Prostate Cancer Prostatic Dis
  doi: 10.1038/pcan.2011.52
– volume: 52
  start-page: 1089
  year: 2006
  end-page: 1095
  ident: CR9
  article-title: APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer
  publication-title: Clin Chem
  doi: 10.1373/clinchem.2005.063289
– volume: 18
  start-page: 459
  year: 2012
  end-page: 465
  ident: CR36
  article-title: The role of urine prostate cancer antigen 3 mRNA levels in the diagnosis of prostate cancer among Hong Kong Chinese patients
  publication-title: Hong Kong Med J
– volume: 44
  start-page: 8
  year: 2003
  end-page: 15
  ident: CR6
  article-title: DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer
  publication-title: Eur Urol
  doi: 10.1016/S0302-2838(03)00201-X
– volume: 71
  start-page: 700
  year: 2011
  end-page: 710
  ident: CR31
  article-title: A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer
  publication-title: Prostate
  doi: 10.1002/pros.21286
– volume: 70
  start-page: 1760
  year: 2010
  end-page: 1767
  ident: CR26
  article-title: PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine
  publication-title: Prostate
  doi: 10.1002/pros.21211
– volume: 90
  start-page: 97
  year: 2011
  end-page: 100
  ident: CR27
  article-title: The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population
  publication-title: Exp Mol Pathol
  doi: 10.1016/j.yexmp.2010.10.009
– volume: 59
  start-page: 5975
  year: 1999
  end-page: 5979
  ident: CR3
  article-title: DD3: a new prostate-specific gene, highly overexpressed in prostate cancer
  publication-title: Cancer Res
– volume: 62
  start-page: 34
  year: 2003
  end-page: 43
  ident: CR56
  article-title: New targets for therapy in prostate cancer: differential display code 3 (DD3 (PCA3)), a highly prostate cancer-specific gene
  publication-title: Urology
  doi: 10.1016/S0090-4295(03)00759-3
– volume: 64
  start-page: 311
  year: 2004
  end-page: 315
  ident: CR7
  article-title: uPM3, a new molecular urine test for the detection of prostate cancer
  publication-title: Urology
  doi: 10.1016/j.urology.2004.03.052
– volume: 64
  start-page: 9
  year: 2014
  end-page: 29
  ident: CR2
  article-title: Cancer statistics, 2014
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21208
– volume: 184
  start-page: 1947
  year: 2010
  end-page: 1952
  ident: CR21
  article-title: PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial
  publication-title: J Urol
  doi: 10.1016/j.juro.2010.06.098
– volume: 59
  start-page: 81
  year: 2011
  end-page: 87
  ident: CR33
  article-title: Prostate cancer detection in the “grey area” of prostate-specific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and Chun’s nomogram, two risk estimators incorporating prostate cancer antigen 3
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2010.09.036
– volume: 191
  start-page: 1743
  year: 2014
  end-page: 1748
  ident: CR49
  article-title: Urinary PCA3 as a predictor of prostate cancer in a cohort of 3,073 men undergoing initial prostate biopsy
  publication-title: J Urol
  doi: 10.1016/j.juro.2013.12.005
– volume: 13
  start-page: 939
  year: 2007
  end-page: 943
  ident: CR10
  article-title: The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-06-2679
– volume: 339
  start-page: b2700
  year: 2009
  ident: CR4
  article-title: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
  publication-title: BMJ
  doi: 10.1136/bmj.b2700
– volume: 58
  start-page: 475
  year: 2010
  end-page: 481
  ident: CR25
  article-title: Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2010.06.039
– volume: 59
  start-page: 61
  year: 2011
  end-page: 71
  ident: CR53
  article-title: EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2010.10.039
– volume: 73
  start-page: 227
  year: 2013
  end-page: 235
  ident: CR46
  article-title: Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy
  publication-title: Prostate
  doi: 10.1002/pros.22561
– volume: 14
  start-page: 235
  year: 2009
  end-page: 243
  ident: CR19
  article-title: The combination of urine DD3(PCA3) mRNA and PSA mRNA as molecular markers of prostate cancer
  publication-title: Biomarkers
  doi: 10.1080/13547500902807306
– volume: 58
  start-page: 475
  year: 2010
  ident: BFsrep25776_CR25
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2010.06.039
– volume: 90
  start-page: 97
  year: 2011
  ident: BFsrep25776_CR27
  publication-title: Exp Mol Pathol
  doi: 10.1016/j.yexmp.2010.10.009
– volume: 190
  start-page: 496
  year: 2013
  ident: BFsrep25776_CR48
  publication-title: J Urol
  doi: 10.1016/j.juro.2013.02.3184
– volume: 12
  start-page: 507
  year: 2012
  ident: BFsrep25776_CR59
  publication-title: BMC cancer
  doi: 10.1186/1471-2407-12-507
– volume: 192
  start-page: 60
  year: 2014
  ident: BFsrep25776_CR50
  publication-title: J Urol
  doi: 10.1016/j.juro.2014.01.030
– volume: 18
  start-page: 200
  year: 2011
  ident: BFsrep25776_CR32
  publication-title: Int J Urol
  doi: 10.1111/j.1442-2042.2010.02711.x
– volume: 115
  start-page: 3879
  year: 2009
  ident: BFsrep25776_CR18
  publication-title: Cancer
  doi: 10.1002/cncr.24447
– volume: 277
  start-page: 36689
  year: 2002
  ident: BFsrep25776_CR62
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M202414200
– volume: 38
  start-page: 489
  year: 2012
  ident: BFsrep25776_CR39
  publication-title: Int Braz J Urol
  doi: 10.1590/S1677-55382012000400008
– volume: 84
  start-page: 227
  year: 2012
  ident: BFsrep25776_CR35
  publication-title: Arch Ital Urol Androl
– volume: 59
  start-page: 280
  year: 2013
  ident: BFsrep25776_CR45
  publication-title: Clin Chem
  doi: 10.1373/clinchem.2012.195560
– volume: 14
  start-page: 235
  year: 2009
  ident: BFsrep25776_CR19
  publication-title: Biomarkers
  doi: 10.1080/13547500902807306
– volume: 181
  start-page: 2508
  year: 2009
  ident: BFsrep25776_CR16
  publication-title: J Urol
  doi: 10.1016/j.juro.2009.01.110
– volume: 179
  start-page: 1587
  year: 2008
  ident: BFsrep25776_CR13
  publication-title: J Urol
  doi: 10.1016/j.juro.2007.11.038
– volume: 191
  start-page: 1743
  year: 2014
  ident: BFsrep25776_CR49
  publication-title: J Urol
  doi: 10.1016/j.juro.2013.12.005
– volume: 69
  start-page: 532
  year: 2007
  ident: BFsrep25776_CR12
  publication-title: Urology
  doi: 10.1016/j.urology.2006.12.014
– volume: 59
  start-page: 81
  year: 2011
  ident: BFsrep25776_CR33
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2010.09.036
– volume: 8
  start-page: 145
  year: 2010
  ident: BFsrep25776_CR54
  publication-title: J Natl Compr Canc Netw
  doi: 10.6004/jnccn.2010.0010
– volume: 64
  start-page: 311
  year: 2004
  ident: BFsrep25776_CR7
  publication-title: Urology
  doi: 10.1016/j.urology.2004.03.052
– volume: 182
  start-page: 2232
  year: 2009
  ident: BFsrep25776_CR55
  publication-title: J Urol
  doi: 10.1016/j.juro.2009.07.093
– volume: 86
  start-page: 306
  year: 2014
  ident: BFsrep25776_CR51
  publication-title: Arch Ital Urol Androl
  doi: 10.4081/aiua.2014.4.306
– volume: 15
  start-page: 100
  year: 2012
  ident: BFsrep25776_CR41
  publication-title: Prostate Cancer Prostatic Dis
  doi: 10.1038/pcan.2011.52
– ident: BFsrep25776_CR57
  doi: 10.1002/pros.21040
– volume: 70
  start-page: 1760
  year: 2010
  ident: BFsrep25776_CR26
  publication-title: Prostate
  doi: 10.1002/pros.21211
– volume: 54
  start-page: 1081
  year: 2008
  ident: BFsrep25776_CR14
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2008.06.071
– volume: 35
  start-page: 589
  year: 2011
  ident: BFsrep25776_CR29
  publication-title: Actas Urol Esp
  doi: 10.1016/j.acuro.2011.04.001
– volume: 73
  start-page: 227
  year: 2013
  ident: BFsrep25776_CR46
  publication-title: Prostate
  doi: 10.1002/pros.22561
– volume: 46
  start-page: 182
  year: 2004
  ident: BFsrep25776_CR8
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2004.06.004
– volume: 315
  start-page: 170
  year: 2012
  ident: BFsrep25776_CR1
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2011.09.035
– volume: 108
  start-page: 1728
  year: 2011
  ident: BFsrep25776_CR30
  publication-title: BJU Int
  doi: 10.1111/j.1464-410X.2011.10202.x
– volume: 184
  start-page: 1947
  year: 2010
  ident: BFsrep25776_CR21
  publication-title: J Urol
  doi: 10.1016/j.juro.2010.06.098
– volume: 185
  start-page: 2119
  year: 2011
  ident: BFsrep25776_CR34
  publication-title: J Urol
  doi: 10.1016/j.juro.2011.01.075
– volume: 73
  start-page: 363
  year: 2009
  ident: BFsrep25776_CR17
  publication-title: Urology
  doi: 10.1016/j.urology.2008.08.459
– volume: 63
  start-page: 201
  year: 2013
  ident: BFsrep25776_CR52
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2012.07.030
– volume: 58
  start-page: 727
  year: 2010
  ident: BFsrep25776_CR22
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2010.06.038
– volume: 85
  start-page: 159
  year: 2010
  ident: BFsrep25776_CR28
  publication-title: Urol Int
  doi: 10.1159/000314078
– volume: 71
  start-page: 700
  year: 2011
  ident: BFsrep25776_CR31
  publication-title: Prostate
  doi: 10.1002/pros.21286
– volume: 188
  start-page: 1726
  year: 2012
  ident: BFsrep25776_CR37
  publication-title: J Urol
  doi: 10.1016/j.juro.2012.07.023
– volume: 52
  start-page: 1089
  year: 2006
  ident: BFsrep25776_CR9
  publication-title: Clin Chem
  doi: 10.1373/clinchem.2005.063289
– volume: 4
  start-page: 5012
  year: 2014
  ident: BFsrep25776_CR63
  publication-title: Sci Rep
  doi: 10.1038/srep05012
– volume: 3
  start-page: 25
  year: 2003
  ident: BFsrep25776_CR5
  publication-title: BMC Med Res Methodol
  doi: 10.1186/1471-2288-3-25
– volume: 8
  start-page: e67687
  year: 2013
  ident: BFsrep25776_CR42
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0067687
– volume: 111
  start-page: 928
  year: 2013
  ident: BFsrep25776_CR44
  publication-title: BJU Int
  doi: 10.1111/j.1464-410X.2012.11683.x
– volume: 73
  start-page: 48
  year: 2013
  ident: BFsrep25776_CR43
  publication-title: Prostate
  doi: 10.1002/pros.22538
– volume: 63
  start-page: 329
  year: 2003
  ident: BFsrep25776_CR60
  publication-title: Cancer research
– volume: 44
  start-page: 8
  year: 2003
  ident: BFsrep25776_CR6
  publication-title: Eur Urol
  doi: 10.1016/S0302-2838(03)00201-X
– volume: 24
  start-page: 1821
  year: 2010
  ident: BFsrep25776_CR20
  publication-title: J Endourol
  doi: 10.1089/end.2010.0196
– volume: 59
  start-page: 61
  year: 2011
  ident: BFsrep25776_CR53
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2010.10.039
– volume: 13
  start-page: 939
  year: 2007
  ident: BFsrep25776_CR10
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-06-2679
– volume: 110
  start-page: 1661
  year: 2012
  ident: BFsrep25776_CR40
  publication-title: BJU Int
  doi: 10.1111/j.1464-410X.2012.11146.x
– volume: 33
  start-page: 553
  year: 2013
  ident: BFsrep25776_CR47
  publication-title: Anticancer Res
– volume: 59
  start-page: 5975
  year: 1999
  ident: BFsrep25776_CR3
  publication-title: Cancer Res
– volume: 67
  start-page: 881
  year: 2007
  ident: BFsrep25776_CR11
  publication-title: Prostate
  doi: 10.1002/pros.20564
– volume: 31
  start-page: 4445
  year: 2011
  ident: BFsrep25776_CR38
  publication-title: Anticancer Res
– volume: 62
  start-page: 2220
  year: 2002
  ident: BFsrep25776_CR61
  publication-title: Cancer Res
– volume: 44
  start-page: 378
  year: 2010
  ident: BFsrep25776_CR24
  publication-title: Scand J Urol Nephrol
  doi: 10.3109/00365599.2010.521187
– volume: 28
  start-page: 677
  year: 2010
  ident: BFsrep25776_CR23
  publication-title: World J Urol
  doi: 10.1007/s00345-010-0580-0
– volume: 4
  start-page: e4995
  year: 2009
  ident: BFsrep25776_CR58
  publication-title: PloS one
  doi: 10.1371/journal.pone.0004995
– volume: 339
  start-page: b2700
  year: 2009
  ident: BFsrep25776_CR4
  publication-title: BMJ
  doi: 10.1136/bmj.b2700
– volume: 62
  start-page: 34
  year: 2003
  ident: BFsrep25776_CR56
  publication-title: Urology
  doi: 10.1016/S0090-4295(03)00759-3
– volume: 18
  start-page: 459
  year: 2012
  ident: BFsrep25776_CR36
  publication-title: Hong Kong Med J
– volume: 68
  start-page: 645
  year: 2008
  ident: BFsrep25776_CR15
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-07-3224
– volume: 64
  start-page: 9
  year: 2014
  ident: BFsrep25776_CR2
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21208
SSID ssj0000529419
Score 2.4727163
SecondaryResourceType review_article
Snippet Previous studies indicate that prostate cancer antigen 3 (PCA3) is highly expressed in prostatic tumors. However, its clinical value has not been...
SourceID pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 25776
SubjectTerms 38
38/77
631/61/54
639/301/1019
Antigens
Antigens, Neoplasm - metabolism
Antigens, Neoplasm - urine
Clinical trials
Humanities and Social Sciences
Humans
Male
Meta-analysis
multidisciplinary
Odds Ratio
Prostate cancer
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - metabolism
Prostatic Neoplasms - urine
ROC Curve
Science
Science (multidisciplinary)
Sensitivity and Specificity
Tumors
Urine
Title Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis
URI https://link.springer.com/article/10.1038/srep25776
https://www.ncbi.nlm.nih.gov/pubmed/27161545
https://www.proquest.com/docview/1898668590
https://www.proquest.com/docview/1788228940
https://pubmed.ncbi.nlm.nih.gov/PMC4861967
Volume 6
WOSCitedRecordID wos000375535000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: DOA
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: M~E
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVPQU
  databaseName: AUTh Library subscriptions: ProQuest Central
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: BENPR
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Biological Science Database
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: M7P
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/biologicalscijournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: 7X7
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Publicly Available Content
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: PIMPY
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Science Database (ProQuest)
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: M2P
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/sciencejournals
  providerName: ProQuest
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LbxMxEB61DUhcoLwDbWQKBy5Ws2vvjpcLgioVHBqtKpDCabX22qJS2YQkReLfM_Y-2qaol1588WR3NjMez8P-BuCdEWTwMpnx2Fnk0piKk1ckuK8KUoxbRijK0GwCp1M1m2V5m3BbtccqO5sYDHU1Nz5HfkhPVGmqkmz8cfGb-65RvrrattDYhgF5NpE_0nUS532OxVexZJR1gEJCHdK2syAl9QgjV7ehG77lzSOSG3XSsP0cP7or47vwsHU82adGUx7Dlq2fwP2mFeXfp3A-6WG_2dyxhb8MQm4oM14rloz-fw_byQQjJ5dV1pceiM9Nug-sZJfY0Ky5F0M_rtgvuy552SKgPIPvx5NvR19424mBm2Qs17xCZVVsMgoutNaJ0VkUO6ToZewcukomWFmaEEobF2mFwsgkQVNWyjhLMZl4Djv1vLYvgaG0UaqxTPwNO52mmSELJ8dak2JIp3EI7zvBFKaFKffdMs6LUC4XquhlOISDnnTRYHP8j2ivE0vRLs9VcSmTIbzpp2lh-WpJWdv5BdEgBR8UjkqiedEoQ_-WGL2jLJMh4DU16Qk8aPf1mfrsZwDvlopC1pQ-822nUFfY2mT-1e3Mv4YH5L-lPIDJ7sHOenlh9-Ge-bM-Wy1HsI0zDKMaweDzZJqfjkLKYRRWiR-RxkH-9ST_8Q_XKx82
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1LT9wwEB4BBbWXtpQ-tqWtKSD1YrGJndipVFUVD4GAFQeQuIXYsQUSZLe7Syv-VH9jZ_ICFsSNQ8-eOI7zeTzj8XwDsGIFKrxEJjz0TnFpbc7RKhKcooLo42aBEllZbEL1evr4ODmYgr9NLgxdq2x0Yqmo876lM_I17FHHsY6S7o_BL05Voyi62pTQqGCx667-oMs2-r6zgf93NQy3Ng_Xt3ldVYDbqCvHPFfa6dAmaCgbYyJrkiD0Ci3xrvfK5zJSucMGoY31gdFKWBlFyma5tt6hfyGw32l4IolZjK4KhgftmQ5FzWSQNARGQq_hNjfARUGMJje3vTu27N0rmRNx2XK723rxv03US3heG9bsZ7US5mHKFa9griq1ebUA55strTnrezagZBc0s5kl1A8Z4otoSZlgaMSz3FFoBedlUu4by9g19zWr8n7w4ZxduHHGs5rh5TUcPcqnvoGZol-4d8CUdEFsVBZRBqGJ48SiBpddYxD40hvVga8NEFJb07BTNZDztLwOIHTaYqYDX1rRQcU9cp_QYgODtFY_o_QaAx1YaptRcVA0KCtc_xJlFDpX6G5LlHlbga99S6jIEZBRB9QtWLYCREp-u6U4Oy3JyaVGlzzGz1xuAHxjWJODf__w4D_D0-3D_b10b6e3-wGeoa0a85I4dxFmxsNL9xFm7e_x2Wj4qVyHDE4eG8__AFFQd90
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1LTxsxEB5BKKgXoC3Q8Kr7knqxkl17114khFAhakQb5dBK9LRde22BBJuQBBB_jV_HeF9AqHrj0LMnG-_uN-NvduxvAD5phgEv4hH1rRGUa51SZEWMuqog5riJJ1iSN5sQvZ48Po76M3BbnYVx2yqrmJgH6nSg3TfyFl5RhqEMonbLltsi-gedveEFdR2kXKW1aqdRQOTI3Fxj-jbe7R7gu_7s-53Dn1-_0bLDANVBm09oKqSRvo6QNCulAq0iz7cCWXnbWmFTHojU4ACTSltPScE0DwKhk1RqazDXYHjdWZhDSs79Bsz1uz_6v-svPK6Gxr2okjNisoWL3hBdxOmbPFwEnzDbpxs0p6q0-eLXWfqfH9syLJaUm-wXPvIKZkz2GuaLJpw3b-DssBY8JwNLhu4YDBJwop0_jAgizwmWEkaQ3pPUuKILPqNpux2SkHtVbFKcCMIfp-TcTBKalNovK_DrWW51FRrZIDNvgQhuvFCJJHBnC1UYRhpjO28rhS7BrRJN-FKBItalQLvrE3IW5xsFmIxr_DThQ206LFRJ_ma0WUEiLgPTOL7HQxPe18MYUlydKMnM4BJtBKZdmIhztFkrgFj_iy9cisCDJohHEK0NnFz545Hs9CSXLecSk_UQb_NjBeYH05qe_Pq_J_8OFhDG8fdu72gDXiKJDWmuqLsJjcno0mzBC301OR2PtkunJPDnuQF9BxqigiY
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+prostate+cancer+antigen+3+for+detecting+prostate+cancer%3A+a+systematic+review+and+meta-analysis&rft.jtitle=Scientific+reports&rft.au=Cui%2C+Yong&rft.au=Cao%2C+Wenzhou&rft.au=Li%2C+Quan&rft.au=Shen%2C+Hua&rft.date=2016-05-10&rft.pub=Nature+Publishing+Group+UK&rft.eissn=2045-2322&rft.volume=6&rft.issue=1&rft_id=info:doi/10.1038%2Fsrep25776&rft.externalDocID=10_1038_srep25776
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon